References

  1. Viatris data on file (myl_xen_dof_v1).
  2. Xenidate XL. Summary of Product characteristics – all doses. March 2022.
  3. NICE. Methylphenidate hydrochloride. https://bnf.nice.org.uk/medicinal-forms/methylphenidate-hydrochloride.html (last accessed March 2022).
  4. Xenidate XL. Patient Information Leaflets – all doses. March 2022.
  5. NHS. Medicines information. Available at: https://www.nhs.uk/conditions/medicines-information/ (accessed March 2022).
  6. Ibrahim K & Donyai P. Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades. J Atten Disord. 2015;19(7):551–68.
  7. Siebelink NM et al. Mindfulness for children with ADHD and Mindful Parenting (MindChamp):
    Protocol of a randomised controlled trial comparing a family Mindfulness-Based Intervention as an add-on to care-as-usual with care-as usual only. BMC Psychiatry 2018;18:237 https://doi.org/10.1186/s12888-018-1811-y.
Viatris

If you get any side effects or have a device failure, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Please report side effects or device failures with any medicine or vaccine to the medicines regulator MHRA through the Yellow Card Scheme.
It is easiest and quickest to report side effects and device failures online via the Yellow Card website:  https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Alternatively, prepaid Yellow Cards for reporting are available by writing to FREEPOST YELLOW CARD (no other address details necessary), by emailing yellowcard@mhra.gov.uk, by telephoning the Commission on Human Medicines (CHM) free phone line: 0800-731-6789, or by downloading and printing a form from the Yellow Card section of the MHRA website. You can also report side effects and device failures direct to the marketing authorisation holder at pv.uk@viatris.com.

| Contact us | Privacy policy | T&Cs | Data Protection | Sitemap

Copyright © 2022 Viatris Inc. All rights reserved.
The content on this site is intended for use with UK members of the public only.
Concerta XL® is a registered trademark of Janssen-Cilag Ltd
This website is owned and managed by Viatris

Please note, while efforts have been made to choose reputable sources, Viatris cannot take responsibility on these pages maintained by external providers.
We recommend that you read the full patient information leaftlet leaflet carefully before using Xenidate XL

Xenidate XL Indication: As part of a comprehensive treatment programme for Attention Deficit/Hyperactivity Disorder (ADHD) in children aged 6 years and over and adolescents when remedial measures alone prove insufficient. Treatment must be under the supervision of a specialist in childhood behavioural disorders

MET-2021-0013
Date of Preparation: June 2022.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)